Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource, 1 online resource.

Language: Englisch

Bibliographic citation: Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead ; volume:24 ; number:5 ; day:18 ; month:4 ; year:2023 ; pages:466-467 ; date:5.2023
Current treatment options in oncology ; 24, Heft 5 (18.4.2023), 466-467, 5.2023

Creator: Grinda, Thomas
Rassy, Elie
Pistilli, Barbara

Contributor: SpringerLink (Online service)

DOI: 10.1007/s11864-023-01092-1

URN: urn:nbn:de:101:1-2023090208593693767836

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:49 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Grinda, Thomas
Rassy, Elie
Pistilli, Barbara
SpringerLink (Online service)

Other Objects (12)

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

The First FDA-Approved Antibody-Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

Antibody–drug conjugates in ovarian cancer

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

The First FDA-Approved Antibody-Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

Antibody–drug conjugates in ovarian cancer

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

The First FDA-Approved Antibody-Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

Antibody–drug conjugates in ovarian cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

The First FDA-Approved Antibody-Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

Antibody–drug conjugates in ovarian cancer

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

The First FDA-Approved Antibody-Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

Antibody–drug conjugates in ovarian cancer

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

The First FDA-Approved Antibody-Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

Antibody–drug conjugates in ovarian cancer

Related objects

Reset password